Company Overview of Fidia Farmaceutici s.p.a.
Fidia Farmaceutici s.p.a. engages in the research and development, production, and sale of medicinal products, medical devices, and nutritional supplements in Europe, North America, Latin America, the Middle East, and Far East. The company’s product portfolio focuses primarily on therapeutic areas, including joint healthcare; tissue repair and dermatology; a line of health and wellness products in women's hygiene; and central nervous system pathologies. It also offers viscosupplementation that includes products primarily based on hyaluronic acid and its derivatives for the treatment of joint healthcare, advanced wound care, dermatology, neurology, and dermo-aesthetics problems; and branded p...
Via Ponte della Fabbrica 3/A
Abano Terme, PD 35031
Founded in 1946
Key Executives for Fidia Farmaceutici s.p.a.
Compensation as of Fiscal Year 2016.
Fidia Farmaceutici s.p.a. Key Developments
Fidia Farmaceutici S.p.A. Introduces Hymovi
Feb 25 16
Fidia Farmaceutici S.p.A. will introduce Hymovis (high molecular weight viscoelastic hyaluronan) at the Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) in Orlando, March 1, to March 5, 2016. Hymovis is a next-generation of HA-based intra-articular (IA) therapy indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics. The product has a shorter treatment cycle of only two intra-articular injections as compared to many other IA HA viscosupplement regimens to provide pain relief for the patient. Scientists from Fidia Farmaceutici S.p.A. and the research group led by Dr. Lawrence Bonassar, Professor in the Meinig School of Biomedical Engineering at Cornell University worked together to verify the optimal lubricating characteristics of the HA derivative. Hymovis was bioengineered using a proprietary process that results in a natural hyaluronan similar to the hyaluronan found in the synovial fluid present in human joints. The formulation allows the molecule to recover its original structure, even after repetitive mechanical stress. Due to reversible hydrophobic interactions, the non-crosslinked Hymovis has increased elasticity, viscosity and residence time in the joint.
Fidia Farmaceutici Signs Partnership Agreement with APR Applied Pharma Research to Market APR Paediatric Products in Italy
Jul 3 15
Fidia Farmaceutici and APR Applied Pharma Research have entered into a partnership agreement allowing Fidia to market APR paediatric products in Italy. Under the terms of the deal, Fidia will be granted rights to commercialize APR's global over-the-counter (OTC) and prescription brand, Halykoo, which caters for a range of paediatric skin and mucosal health treatments. The Halykoo brand will be available in Italy from 2016. The partnership complements Fidia's existing therapeutic portfolio in the paediatrics market segment.
Similar Private Companies By Industry
Recent Private Companies Transactions
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries